| Title |
Reversal of direct oral anticoagulants
|
|---|---|
| Published in |
Vascular Health and Risk Management, July 2017
|
| DOI | 10.2147/vhrm.s138890 |
| Pubmed ID | |
| Authors |
Mosaad Almegren |
| Abstract |
Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for effective reversal agents has increased, particularly for life-threatening bleeding episodes related to DOACs or to reverse medication effects during urgent interventions. In the absence of specific reversal agents, prothrombin complex concentrate (PCC) and activated PCC are reasonable options to reverse bleeding associated with DOACs. However, high-quality clinical evidence is lacking. Idarucizumab is the only agent approved by the US Food and Drug Administration to reverse the effects of dabigatran; andexanet alfa and ciraparantag are also under evaluation as reversal agents for DOACs. This review summarizes the current evidence for nonspecific and specific reversal of DOACs. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 113 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 17% |
| Student > Master | 16 | 14% |
| Other | 14 | 12% |
| Researcher | 8 | 7% |
| Student > Postgraduate | 7 | 6% |
| Other | 18 | 16% |
| Unknown | 31 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Agricultural and Biological Sciences | 4 | 4% |
| Neuroscience | 3 | 3% |
| Other | 10 | 9% |
| Unknown | 36 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2019.
All research outputs
#15,745,807
of 25,382,440 outputs
Outputs from Vascular Health and Risk Management
#465
of 804 outputs
Outputs of similar age
#179,938
of 326,871 outputs
Outputs of similar age from Vascular Health and Risk Management
#4
of 13 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.